Trial Profile
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Carcinoma; Inflammatory breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development
- 01 Jun 2008 Final results presented at ASCO 2008.
- 08 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 14 Dec 2007 The expected completion date for this trial is now 1 Dec 2007 according to ClinicalTrials.gov.